Understanding Your Options

Mesothelioma treatment depends on several factors: the type and stage of disease, cell type, overall health, and patient preferences. Most patients receive a combination of treatments, known as multimodal therapy, which typically produces better outcomes than any single approach.

Early-stage patients who receive multimodal treatment (surgery + chemotherapy + immunotherapy) can achieve median survival of 32 months, nearly triple the overall median survival.

Treatment Options

Surgery

Surgical options for eligible patients, including pleurectomy/decortication and extrapleural pneumonectomy.

Typical candidates: Early-stage patients in good health Learn more →

Chemotherapy

Standard first-line treatment using cisplatin and pemetrexed, either alone or combined with other therapies.

Typical candidates: Most mesothelioma patients Learn more →

Immunotherapy

FDA-approved checkpoint inhibitors (Opdivo + Yervoy) that help the immune system fight cancer.

Typical candidates: Unresectable pleural mesothelioma Learn more →

Radiation Therapy

Used to shrink tumors, relieve symptoms, or prevent recurrence after surgery.

Typical candidates: Various stages, often combined with other treatments Learn more →

Clinical Trials

Access to emerging treatments including gene therapy, CAR T-cell therapy, and new drug combinations.

Typical candidates: Varies by trial requirements Learn more →

Palliative Care

Treatments focused on symptom relief and quality of life at any disease stage.

Typical candidates: All patients at any stage Learn more →

Patient Decision Guides

Long-form clinical guides for the treatment-decision questions newly-diagnosed people and their families face. Each guide draws on the primary trial literature and is reviewed by the named mesothelioma authority profiled at the byline.

First-Line Treatment Decision (2026)

Choosing between nivolumab+ipilimumab and pembrolizumab+chemo for newly-diagnosed pleural mesothelioma. CheckMate-743 5-year update and KEYNOTE-483/IND-227 applied to the decision.

Surgery: P/D vs EPP

How surgical decisions are made between lung-sparing pleurectomy/decortication and extrapleural pneumonectomy. The MARS controversy and the move toward P/D at high-volume centers.

HIPEC for Peritoneal Mesothelioma

Cytoreductive surgery and HIPEC for peritoneal disease. Eligibility (PCI score, performance status), outcomes from the Yan and Sugarbaker series, and the center-volume effect.

Clinical Trial Enrollment

Practical guide to finding, decoding, and joining a mesothelioma clinical trial. Reading ClinicalTrials.gov entries, eligibility criteria, and what enrollment actually involves.

Second-Line After Progression

What to consider when first-line treatment stops working. Standard 2L options (CONFIRM, NIBIT-MESO-1), investigational agents in clinical trials, and how the decision is framed.

Related Articles

Finding Treatment

Mesothelioma is rare, and treatment is most effective at specialized cancer centers with experienced oncologists. Consider seeking care or a second opinion from a center that regularly treats mesothelioma patients.

Find mesothelioma specialists →